- Home
- MCRB vs MBINM Comparison
MCRB vs MBINM Comparison
Compare MCRB & MBINM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- MBINM
- Stock Information
- Founded
- MCRB 2010
- MBINM N/A
- Country
- MCRB United States
- MBINM United States
- Employees
- MCRB N/A
- MBINM 618
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- MBINM Major Banks
- Sector
- MCRB Health Care
- MBINM Finance
- Exchange
- MCRB Nasdaq
- MBINM Nasdaq
- Market Cap
- MCRB 148.4M
- MBINM N/A
- IPO Year
- MCRB 2015
- MBINM N/A
- Fundamental
- Price
- MCRB $0.89
- MBINM $26.14
- Analyst Decision
- MCRB Buy
- MBINM
- Analyst Count
- MCRB 4
- MBINM 0
- Target Price
- MCRB $5.63
- MBINM N/A
- AVG Volume (30 Days)
- MCRB 3.4M
- MBINM N/A
- Earning Date
- MCRB 11-13-2024
- MBINM N/A
- Dividend Yield
- MCRB N/A
- MBINM N/A
- EPS Growth
- MCRB N/A
- MBINM N/A
- EPS
- MCRB N/A
- MBINM N/A
- Revenue
- MCRB $126,325,000.00
- MBINM N/A
- Revenue This Year
- MCRB N/A
- MBINM N/A
- Revenue Next Year
- MCRB N/A
- MBINM N/A
- P/E Ratio
- MCRB N/A
- MBINM N/A
- Revenue Growth
- MCRB 12856.41
- MBINM N/A
- 52 Week Low
- MCRB $0.54
- MBINM N/A
- 52 Week High
- MCRB $2.05
- MBINM N/A
- Technical
- Relative Strength Index (RSI)
- MCRB 58.98
- MBINM 50.89
- Support Level
- MCRB $0.87
- MBINM $25.73
- Resistance Level
- MCRB $1.01
- MBINM $26.20
- Average True Range (ATR)
- MCRB 0.10
- MBINM 0.33
- MACD
- MCRB 0.03
- MBINM -0.01
- Stochastic Oscillator
- MCRB 78.40
- MBINM 43.62
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About MBINM Merchants Bancorp Depositary Shares Each Representing a 1/40th Interest in a Share of 8.25% Fixed-Rate Reset Series D Non-Cumulative Perpetual Preferred Stock
Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and Banking segment that provides a wide range of financial products and services to consumers and businesses, including commercial and other consumer loan products.